Table 2 Demographic and clinical characteristics of the validation cohort
Feature | Preclinical SSc (n = 50) | Non-progressors (n = 30) | Progressors (n = 20) |
|---|---|---|---|
Age, years | 55.9 ± 14.04 | 56.8 ± 13.18 | 54.55 ± 15.15 |
Females, n (%) | 44 (88) | 26 (86.7) | 18 (90) |
Ethnicity Caucasian, n (%) | 50 (100) | 30 (100) | 20 (100) |
ANA, n (%) | 47 (94) | 28 (93) | 19 (95) |
ACA, n (%) | 32 (64) | 17 (57) | 15 (75) |
Anti-topoisomerase I, n (%) | 8 (16%) | 3 (1) | 5 (25) |
Other autoantibodies, n (%) | 20 (40) | 11 (36.67) | 9 (45) |
RP duration, months | 128.4 ± 115.7 | 154.3 ± 120.8 | 90 ± 95.41 |
FVC, % predicted | 115.6 ± 16.04 | 116.7 ± 17.8 | 112.5 ± 12.8 |
DLCO, % predicted | 84.2 ± 17.2 | 86.9 ± 17 | 80.1 ± 16.7 |
Evolution, n (%) | 20 (40) | 0 (0) | 20 (100) |
Skin progression, n (%) | 16 (32) | 0 | 16 (80) |
GERD, n (%) | 19 (38) | 9 (30) | 12 (60) |
Telangiectasia, n (%) | 6 (12) | 0 | 6 (30) |
Low-dose aspirin, n (%) | 42 (84) | 26 (87) | 16 (80) |
CCB, n (%) | 36 (72) | 21 (70) | 15 (75) |